FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1739-1746 November 28, 2002 Number 22 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Murray, H. W. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Jacobs, S. PubMed Citation

ABSTRACT

Background There are 500,000 cases per year of visceral leishmaniasis, which occurs primarily in the Indian subcontinent. Almost all untreated patients die, and all the effective agents have been parenteral. Miltefosine is an oral agent that has been shown in small numbers of patients to have a favorable therapeutic index for Indian visceral leishmaniasis. We performed a clinical trial in India comparing miltefosine with the most effective standard treatment, amphotericin B.

Methods The study was a randomized, open-label comparison, in which 299 patients 12 years of age or older received orally administered miltefosine (50 or 100 mg [approximately 2.5 mg per kilogram of body weight] daily for 28 days) and 99 patients received intravenously administered amphotericin B (1 mg per kilogram every other day for a total of 15 injections).

Results The groups were well matched in terms of age, weight, proportion with previous failure of treatment for leishmaniasis, parasitologic grade of splenic aspirate, and splenomegaly. At the end of treatment, splenic aspirates were obtained from 293 patients in the miltefosine group and 98 patients in the amphotericin B group. No parasites were identified, for an initial cure rate of 100 percent. By six months after the completion of treatment, 282 of the 299 patients in the miltefosine group (94 percent [95 percent confidence interval, 91 to 97]) and 96 of the 99 patients in the amphotericin B group (97 percent) had not had a relapse; these patients were classified as cured. Vomiting and diarrhea, generally lasting one to two days, occurred in 38 percent and 20 percent of the patients in the miltefosine group, respectively.

Conclusions Oral miltefosine is an effective and safe treatment for Indian visceral leishmaniasis. Miltefosine may be particularly advantageous because it can be administered orally. It may also be helpful in regions where parasites are resistant to current agents.

Source Information

From the Institutes of Medical Sciences, Banaras Hindu University, Varanasi (S.S.); the Kala-azar Research Center, Brahmpura, Muzaffarpur (T.K.J.); and Balaji Utthan Sanastan, Patna (C.P.T.) — all in India; Zentaris–Asta Medica, Frankfurt am Main, Germany (J.E., H.S., C.F., K.J.); the London School of Hygiene and Tropical Medicine, London (A.B.); and the Walter Reed Army Institute of Research, Silver Spring, Md. (J.B.).

Address reprint requests to Dr. Berman at the National Center for Complementary and Alternative Medicine, 6707 Democracy Blvd., Ste. 401, Bethesda, MD 20892, or at bermanjo{at}mail.nih.gov.

Full Text of this Article

Related Letters:

Miltefosine for Indian Visceral Leishmaniasis
Agarwal P. K., Roca B., Sundar S., Berman J.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:857-858, Feb 27, 2003. Correspondence

This article has been cited by other articles:

• Berman, J. (2009). ABLE: A New and Improved Amphotericin B for Visceral Leishmaniasis?. Am J Trop Med Hyg 80: 689-690 [Full Text]  
• Sundar, S., Singh, A., Agarwal, D., Rai, M., Agrawal, N., Chakravarty, J. (2009). Safety and Efficacy of High-Dose Infusions of a Preformed Amphotericin B Fat Emulsion for Treatment of Indian Visceral Leishmaniasis. Am J Trop Med Hyg 80: 700-703 [Abstract] [Full Text]  
• Guffanti, M., Gaiera, G., Bossolasco, S., Ceserani, N., Ratti, D., Cinque, P., Salmaso, F., Gianotti, N., Lazzarin, A. (2008). Post-Kala-Azar Dermal Leishmaniasis in an HIV-1-Infected Woman: Recovery after Amphotericin B Following Failure of Oral Miltefosine. Am J Trop Med Hyg 79: 715-718 [Abstract] [Full Text]  
• Kim, J.-H., Jung, S.-Y., Lee, Y.-J., Song, K.-J., Kwon, D., Kim, K., Park, S., Im, K.-I., Shin, H.-J. (2008). Effect of Therapeutic Chemical Agents In Vitro and on Experimental Meningoencephalitis Due to Naegleria fowleri. Antimicrob. Agents Chemother. 52: 4010-4016 [Abstract] [Full Text]  
• Dorlo, T. P. C., van Thiel, P. P. A. M., Huitema, A. D. R., Keizer, R. J., de Vries, H. J. C., Beijnen, J. H., de Vries, P. J. (2008). Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients. Antimicrob. Agents Chemother. 52: 2855-2860 [Abstract] [Full Text]  
• Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Canavate, C., Dedet, J.-P., Gradoni, L., Ter Horst, R., Lopez-Velez, R., Moreno, J. (2008). The Relationship between Leishmaniasis and AIDS: the Second 10 Years. Clin. Microbiol. Rev. 21: 334-359 [Abstract] [Full Text]  
• Soto, J., Rea, J., Balderrama, M., Toledo, J., Soto, P., Valda, L., Berman, J. D. (2008). Efficacy of Miltefosine for Bolivian Cutaneous Leishmaniasis. Am J Trop Med Hyg 78: 210-211 [Abstract] [Full Text]  
• Basu, R., Bhaumik, S., Haldar, A. K., Naskar, K., De, T., Dana, S. K., Walden, P., Roy, S. (2007). Hybrid Cell Vaccination Resolves Leishmania donovani Infection by Eliciting a Strong CD8+ Cytotoxic T-Lymphocyte Response with Concomitant Suppression of Interleukin-10 (IL-10) but Not IL-4 or IL-13. Infect. Immun. 75: 5956-5966 [Abstract] [Full Text]  
• Krolewiecki, A. J., Romero, H. D., Cajal, S. P., Abraham, D., Mimori, T., Matsumoto, T., Juarez, M., Taranto, N. J. (2007). A Randomized Clinical Trial Comparing Oral Azithromycin and Meglumine Antimoniate for the Treatment of American Cutaneous Leishmaniasis Caused by Leishmania (Viannia) braziliensis. Am J Trop Med Hyg 77: 640-646 [Abstract] [Full Text]  
• Sundar, S., Jha, T.K., Thakur, C. P., Sinha, P. K., Bhattacharya, S. K. (2007). Injectable Paromomycin for Visceral Leishmaniasis in India. NEJM 356: 2571-2581 [Abstract] [Full Text]  
• MITTAL, M. K., RAI, S., ASHUTOSH, , RAVINDER, , GUPTA, S., SUNDAR, S., GOYAL, N. (2007). CHARACTERIZATION OF NATURAL ANTIMONY RESISTANCE IN LEISHMANIA DONOVANI ISOLATES. Am J Trop Med Hyg 76: 681-688 [Abstract] [Full Text]  
• Eibl, K. H., Lewis, G. P., Betts, K., Linberg, K. A., Gandorfer, A., Kampik, A., Fisher, S. K. (2007). The Effect of Alkylphosphocholines on Intraretinal Proliferation Initiated by Experimental Retinal Detachment. IOVS 48: 1305-1311 [Abstract] [Full Text]  
• Piscopo, T. V, Mallia Azzopardi, C. (2007). Leishmaniasis.. Postgrad. Med. J. 83: 649-657 [Abstract] [Full Text]  
• Menez, C., Buyse, M., Besnard, M., Farinotti, R., Loiseau, P. M., Barratt, G. (2006). Interaction between Miltefosine and Amphotericin B: Consequences for Their Activities towards Intestinal Epithelial Cells and Leishmania donovani Promastigotes In Vitro. Antimicrob. Agents Chemother. 50: 3793-3800 [Abstract] [Full Text]  
• Piscopo, T V, Mallia, A C (2006). Leishmaniasis.. Postgrad. Med. J. 82: 649-657 [Abstract] [Full Text]  
• Perez-Victoria, J. M., Cortes-Selva, F., Parodi-Talice, A., Bavchvarov, B. I., Perez-Victoria, F. J., Munoz-Martinez, F., Maitrejean, M., Costi, M. P., Barron, D., Di Pietro, A., Castanys, S., Gamarro, F. (2006). Combination of Suboptimal Doses of Inhibitors Targeting Different Domains of LtrMDR1 Efficiently Overcomes Resistance of Leishmania spp. to Miltefosine by Inhibiting Drug Efflux.. Antimicrob. Agents Chemother. 50: 3102-3110 [Abstract] [Full Text]  
• Roberts, M. T. M. (2006). Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment. Br Med Bull 75-76: 115-130 [Abstract] [Full Text]  
• Widmer, F., Wright, L. C., Obando, D., Handke, R., Ganendren, R., Ellis, D. H., Sorrell, T. C. (2006). Hexadecylphosphocholine (Miltefosine) Has Broad-Spectrum Fungicidal Activity and Is Efficacious in a Mouse Model of Cryptococcosis. Antimicrob. Agents Chemother. 50: 414-421 [Abstract] [Full Text]  
• Seifert, K., Croft, S. L. (2006). In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs. Antimicrob. Agents Chemother. 50: 73-79 [Abstract] [Full Text]  
• Croft, S. L., Sundar, S., Fairlamb, A. H. (2006). Drug Resistance in Leishmaniasis. Clin. Microbiol. Rev. 19: 111-126 [Abstract] [Full Text]  
• Eibl, K. H., Kook, D., Priglinger, S., Haritoglou, C., Yu, A., Kampik, A., Welge-Lussen, U. (2006). Inhibition of Human Retinal Pigment Epithelial Cell Attachment, Spreading, and Migration by Alkylphosphocholines. IOVS 47: 364-370 [Abstract] [Full Text]  
• Nakayama, H., Loiseau, P. M., Bories, C., Torres de Ortiz, S., Schinini, A., Serna, E., Rojas de Arias, A., Fakhfakh, M. A., Franck, X., Figadere, B., Hocquemiller, R., Fournet, A. (2005). Efficacy of Orally Administered 2-Substituted Quinolines in Experimental Murine Cutaneous and Visceral Leishmaniases. Antimicrob. Agents Chemother. 49: 4950-4956 [Abstract] [Full Text]  
• JHA, T. K., SUNDAR, S., THAKUR, C. P., FELTON, J. M., SABIN, A. J., HORTON, J. (2005). A PHASE II DOSE-RANGING STUDY OF SITAMAQUINE FOR THE TREATMENT OF VISCERAL LEISHMANIASIS IN INDIA. Am J Trop Med Hyg 73: 1005-1011 [Abstract] [Full Text]  
• Al-Mohammed, H. I., Chance, M. L., Bates, P. A. (2005). Production and Characterization of Stable Amphotericin-Resistant Amastigotes and Promastigotes of Leishmania mexicana. Antimicrob. Agents Chemother. 49: 3274-3280 [Abstract] [Full Text]  
• Dondji, B., Perez-Jimenez, E., Goldsmith-Pestana, K., Esteban, M., McMahon-Pratt, D. (2005). Heterologous Prime-Boost Vaccination with the LACK Antigen Protects against Murine Visceral Leishmaniasis. Infect. Immun. 73: 5286-5289 [Abstract] [Full Text]  
• YARDLEY, V., CROFT, S. L., DE DONCKER, S., DUJARDIN, J.-C., KOIRALA, S., RIJAL, S., MIRANDA, C., LLANOS-CUENTAS, A., CHAPPUIS, F. (2005). THE SENSITIVITY OF CLINICAL ISOLATES OF LEISHMANIA FROM PERU AND NEPAL TO MILTEFOSINE. Am J Trop Med Hyg 73: 272-275 [Abstract] [Full Text]  
• Maurya, R., Singh, R. K., Kumar, B., Salotra, P., Rai, M., Sundar, S. (2005). Evaluation of PCR for Diagnosis of Indian Kala-Azar and Assessment of Cure. J. Clin. Microbiol. 43: 3038-3041 [Abstract] [Full Text]  
• El Fadili, K., Messier, N., Leprohon, P., Roy, G., Guimond, C., Trudel, N., Saravia, N. G., Papadopoulou, B., Legare, D., Ouellette, M. (2005). Role of the ABC Transporter MRPA (PGPA) in Antimony Resistance in Leishmania infantum Axenic and Intracellular Amastigotes. Antimicrob. Agents Chemother. 49: 1988-1993 [Abstract] [Full Text]  
• Murray, H. W. (2005). Prevention of Relapse after Chemotherapy in a Chronic Intracellular Infection: Mechanisms in Experimental Visceral Leishmaniasis. J. Immunol. 174: 4916-4923 [Abstract] [Full Text]  
• Richard, D., Leprohon, P., Drummelsmith, J., Ouellette, M. (2004). Growth Phase Regulation of the Main Folate Transporter of Leishmania infantum and Its Role in Methotrexate Resistance. J. Biol. Chem. 279: 54494-54501 [Abstract] [Full Text]  
• MURRAY, H. W. (2004). TREATMENT OF VISCERAL LEISHMANIASIS IN 2004. Am J Trop Med Hyg 71: 787-794 [Abstract] [Full Text]  
• Savoia, D., Avanzini, C., Allice, T., Callone, E., Guella, G., Dini, F. (2004). Antimicrobial Activity of Euplotin C, the Sesquiterpene Taxonomic Marker from the Marine Ciliate Euplotes crassus. Antimicrob. Agents Chemother. 48: 3828-3833 [Abstract] [Full Text]  
• Verma, N. K., Dey, C. S. (2004). Possible Mechanism of Miltefosine-Mediated Death of Leishmania donovani. Antimicrob. Agents Chemother. 48: 3010-3015 [Abstract] [Full Text]  
• Eibl, K. H., Banas, B., Kook, D., Ohlmann, A. V., Priglinger, S., Kampik, A., Welge-Luessen, U. C. (2004). Alkylphosphocholines: A New Therapeutic Option in Glaucoma Filtration Surgery. IOVS 45: 2619-2624 [Abstract] [Full Text]  
• De Siervi, A., Marinissen, M., Diggs, J., Wang, X.-F., Pages, G., Senderowicz, A. (2004). Transcriptional Activation of p21waf1/cip1 by Alkylphospholipids: Role of the Mitogen-Activated Protein Kinase Pathway in the Transactivation of the Human p21waf1/cip1 Promoter by Sp1. Cancer Res. 64: 743-750 [Abstract] [Full Text]  
• Demicheli, C., Ochoa, R., da Silva, J. B. B., Falcao, C. A. B., Rossi-Bergmann, B., de Melo, A. L., Sinisterra, R. D., Frezard, F. (2004). Oral Delivery of Meglumine Antimoniate-{beta}-Cyclodextrin Complex for Treatment of Leishmaniasis. Antimicrob. Agents Chemother. 48: 100-103 [Abstract] [Full Text]  
• Maes, L., Berghe, D. V., Germonprez, N., Quirijnen, L., Cos, P., De Kimpe, N., Van Puyvelde, L. (2004). In Vitro and In Vivo Activities of a Triterpenoid Saponin Extract (PX-6518) from the Plant Maesa balansae against Visceral Leishmania Species. Antimicrob. Agents Chemother. 48: 130-136 [Abstract] [Full Text]  
• Kapotsis, G.E., Daniil, Z., Sardelis, Z., Stavrakaki, K., Saroglou, G., Pappa, V., Roussos, C., Papiris, S.A. (2004). Fever, rigors and sweats in an immunocompromised male. Eur Respir J 23: 176-178 [Full Text]  
• Brochu, C., Wang, J., Roy, G., Messier, N., Wang, X.-Y., Saravia, N. G., Ouellette, M. (2003). Antimony Uptake Systems in the Protozoan Parasite Leishmania and Accumulation Differences in Antimony-Resistant Parasites. Antimicrob. Agents Chemother. 47: 3073-3079 [Abstract] [Full Text]  
• Agarwal, P. K., Roca, B., Sundar, S., Berman, J. (2003). Miltefosine for Indian Visceral Leishmaniasis. NEJM 348: 857-858 [Full Text]  
• (2003). A New Alternative for Kala-Azar. JWatch Infect. Diseases 2003: 6-6 [Full Text]  
• Murray, H. W. (2002). Kala-Azar -- Progress against a Neglected Disease. NEJM 347: 1793-1794 [Full Text]